Cingulate Inc. (CING) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Cingulate Inc. is a pre-revenue biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The primary product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, and CTx-2103 (buspirone) for anxiety. This report covers the quarterly period ended June 30, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4.79) million | $(3.21) million | $(8.59) million | $(6.18) million |
| Operating Loss | $(4.65) million | $(3.21) million | $(8.36) million | $(6.15) million |
| Cash and Equivalents (End of Period) | $8.90 million | $0.38 million | $8.90 million | $0.38 million |
| Accumulated Deficit | $(117.08) million | $(99.13) million | $(117.08) million | $(99.13) million |
| Debt (Note Payable) | $5.13 million (Current) | $2.53 million (Current) | $5.13 million (Current) | $2.53 million (Current) |
Note: The company has no revenue. Interest expense increased significantly in 2025 due to a $5.48 million promissory note issued in December 2024.
Material Changes vs. Prior Period
- Increased Operating Expenses: Operating expenses rose 45% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 36% year-to-date. This was driven by a 44% increase in R&D expenses (due to clinical close-out activities and regulatory fees for NDA submission) and a 47% increase in G&A expenses (primarily legal and professional fees).
- Capital Raising: The company raised approximately $6.1 million in net proceeds from equity issuances during the first six months of 2025 via its At-The-Market (ATM) program and a purchase agreement with Lincoln Park Capital. The Lincoln Park agreement expired in June 2025 after reaching its $12 million cap.
- Debt Structure: Current liabilities increased significantly due to the Streeterville Capital promissory note, which matured in June 2025. As of June 30, 2025, the outstanding principal plus accrued interest was approximately $5.75 million.
- Lease Obligations: A new 5-year office lease commenced in June 2025, resulting in a new operating lease right-of-use asset of $1.45 million.
Guidance, Outlook, and Material Events
- NDA Submission: On July 31, 2025 (subsequent to period end), the company submitted a New Drug Application (NDA) to the FDA for its lead candidate, CTx-1301.
- Liquidity and Going Concern: Management states that cash on hand ($8.9 million) is sufficient to fund operations into late 2025. An additional $1.5 million is required to advance commercialization into early 2026. The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern within one year without additional funding.
- Management Changes (Subsequent Events):
- On August 7, 2025, the former COO, Laurie A. Myers, was terminated.
- On August 9, 2025, Chairman and CEO Shane Schaffer was charged with aggravated domestic battery.
- On August 14, 2025, the Board placed Schaffer on administrative leave, appointed CFO Jennifer Callahan as Interim CEO, and appointed John A. Roberts as Executive Chairman.
- Debt Restructuring: Subsequent to June 30, 2025, the company exchanged $1.225 million of the Streeterville Capital note principal for 268,738 shares of common stock.
- New Financing: On July 21, 2025, a new $25 million purchase agreement with Lincoln Park Capital was executed.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the specific need for $1.5 million by early 2026.
- Debt Covenants: Review the terms of the Streeterville Capital note, specifically the "Major Trigger Event" clauses that could increase the debt balance by 15% or accelerate repayment upon default.
- Management Stability: Assess the impact of the CEO's legal issues and administrative leave on the company's strategic execution and FDA interactions.
- NDA Review Status: Monitor the FDA's acceptance and review timeline for the CTx-1301 NDA submitted in late July 2025.
- Contingent Liabilities: Note the potential $722,824 contingent bonus liability related to prior salary reductions, which may be paid in cash or equity upon NDA filing.